Advertisement
News
Advertisement

Drug Follows Melanoma Wherever It Goes

Thu, 02/17/2011 - 11:36am
Massachusetts Institute of Technology

A nanoparticle that targets melanoma and highlights cancerous tissue is entering an early-stage clinical trial. Researchers testing the nanotherapeutic agent, which has been under development for over a decade, hope it provides a way to target melanoma and map its spread throughout the body. Researchers have tested the drug in animals and found no toxicity. Safety tests in five melanoma patients should be completed by the end of the year.

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading